Study of Dasatinib (BMS-354825) in Patients With Solid Tumors
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to determine the maximum tolerated dose (MTD) or the
maximum administered dose (MAD) of Dasatinib (BMS-354825) in patients in Japan.